Children and adolescents with Crohn's disease (CD) present often with a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and emotional development of patients underlines the need for a specific management strategy of pediatric-onset CD. To develop the first evidenced based and consensus driven guidelines for pediatric-onset CD an expert panel of 33 IBD specialists was formed after an open call within the European Crohn's and Colitis Organisation and the European Society of Pediatric Gastroenterolog, Hepatology and Nutrition. The aim was to base on a thorough review of existing evidence a state of the art guidance on the medical treatment and long term management of children and adolescents with CD, with individualized treatment algorithms based on a benefit-risk analysis according to different clinical scenarios. In children and adolescents who did not have finished their growth, exclusive enteral nutrition (EEN) is the induction therapy of first choice due to its excellent safety profile, preferable over corticosteroids, which are equipotential to induce remission. The majority of patients with pediatric-onset CD require immunomodulator based maintenance therapy. The experts discuss several factors potentially predictive for poor disease outcome (such as severe perianal fistulizing disease, severe stricturing/penetrating disease, severe growth retardation, panenteric disease, persistent severe disease despite adequate induction therapy), which may incite to an anti-TNF-based top down approach. These guidelines are intended to give practical (whenever possible evidence-based) answers to (pediatric) gastroenterologists who take care of children and adolescents with CD; they are not meant to be a rule or legal standard, since many different clinical scenario exist requiring treatment strategies not covered by or different from these guidelines.

• Klíčová slova
• Crohn's disease, Guidelines, Medical therapy, Pediatric,
• MeSH
• adalimumab MeSH
• algoritmy MeSH
• antibakteriální látky terapeutické užití   MeSH
• antiflogistika nesteroidní terapeutické užití   MeSH
• azathioprin terapeutické užití   MeSH
• Crohnova nemoc terapie   MeSH
• dítě MeSH
• enterální výživa * MeSH
• hormony kůry nadledvin škodlivé účinky   terapeutické užití   MeSH
• humanizované monoklonální protilátky terapeutické užití   MeSH
• imunosupresiva terapeutické užití   MeSH
• indukce remise metody   MeSH
• infliximab MeSH
• kyseliny aminosalicylové terapeutické užití   MeSH
• lidé MeSH
• merkaptopurin terapeutické užití   MeSH
• methotrexát terapeutické užití   MeSH
• mladiství MeSH
• monoklonální protilátky terapeutické užití   MeSH
• thalidomid terapeutické užití   MeSH
• TNF-alfa antagonisté a inhibitory   MeSH
• udržovací chemoterapie metody   MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• mladiství MeSH
• Publikační typ
• časopisecké články MeSH
• směrnice pro lékařskou praxi MeSH
• Názvy látek
• adalimumab MeSH
• antibakteriální látky MeSH
• antiflogistika nesteroidní MeSH
• azathioprin MeSH
• hormony kůry nadledvin MeSH
• humanizované monoklonální protilátky MeSH
• imunosupresiva MeSH
• infliximab MeSH
• kyseliny aminosalicylové MeSH
• merkaptopurin MeSH
• methotrexát MeSH
• monoklonální protilátky MeSH
• thalidomid MeSH
• TNF-alfa MeSH